A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors.

AO-252 - A2A Pharma, OncoCube Therap

Ecaterina Elena Dumbrava; Amber Michelle Kennon; Wintana A Balema; Chaemin Lim; Sridhar Vempati; Sotirios Stergiopoulos; Debra L. Richardson

Apr 25, 2024